Hennion & Walsh Asset Management Inc. Has $6.18 Million Stock Position in Ardelyx, Inc. $ARDX

Hennion & Walsh Asset Management Inc. boosted its stake in Ardelyx, Inc. (NASDAQ:ARDX) by 21.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,211,690 shares of the biopharmaceutical company’s stock after purchasing an additional 210,209 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Ardelyx were worth $6,180,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. First Horizon Corp increased its holdings in Ardelyx by 120.4% in the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 4,319 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Ardelyx during the fourth quarter valued at about $60,000. State of Wyoming bought a new stake in shares of Ardelyx during the second quarter worth about $61,000. PVG Asset Management Corp bought a new stake in shares of Ardelyx during the first quarter worth about $65,000. Finally, Osaic Holdings Inc. increased its stake in shares of Ardelyx by 28.2% in the second quarter. Osaic Holdings Inc. now owns 16,854 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 3,709 shares during the period. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx Stock Performance

Shares of Ardelyx stock opened at $4.00 on Monday. The business has a 50-day moving average price of $5.37 and a two-hundred day moving average price of $6.07. Ardelyx, Inc. has a 1-year low of $3.90 and a 1-year high of $8.40. The company has a current ratio of 3.49, a quick ratio of 3.28 and a debt-to-equity ratio of 1.37. The company has a market cap of $996.76 million, a P/E ratio of -18.18 and a beta of 0.70.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 35.57%. The business had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. During the same period in the prior year, the firm earned ($0.08) earnings per share. The firm’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, analysts anticipate that Ardelyx, Inc. will post -0.1 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ARDX. Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. TD Cowen reduced their target price on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings cut shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Ardelyx in a research note on Friday. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Ardelyx in a report on Tuesday, June 16th. They set a “buy” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Ardelyx currently has an average rating of “Moderate Buy” and a consensus target price of $15.30.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Second-quarter revenue increased 34.3% year over year to approximately $120.9 million, indicating continued commercial growth despite missing the revenue estimate slightly. Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: BTIG Research maintained a Buy rating on ARDX, suggesting substantial long-term upside potential even after reducing its price target from $17 to $14. BTIG Research price target update
• Neutral Sentiment: Ardelyx’s Q2 earnings call and business update provided additional discussion of operating performance and company priorities, but the available report does not identify a specific new catalyst driving the stock. Ardelyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Ardelyx reported a second-quarter loss of $0.07 per share, worse than the expected loss of $0.05, although it improved from a $0.08 loss in the year-ago quarter. Revenue of $120.88 million also narrowly missed estimates of approximately $121.0 million. Ardelyx Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Zacks added ARDX to its Rank #5, or Strong Sell, list, adding to near-term pressure from the earnings miss and the company’s continuing negative profitability metrics. New Strong Sell Stocks for August 7th
• Negative Sentiment: The lower BTIG price target reflects reduced near-term expectations, even though the firm retained its Buy rating. BTIG Research price target update

Insider Activity at Ardelyx

In other news, insider Mike Kelliher sold 7,248 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider owned 357,418 shares of the company’s stock, valued at $2,241,010.86. This trade represents a 1.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $50,147.46. Following the completion of the sale, the insider owned 417,972 shares of the company’s stock, valued at $2,620,684.44. This represents a 1.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 24,572 shares of company stock worth $154,066. Insiders own 5.30% of the company’s stock.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.